Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086605 | 0.88 | TACR1 (0.40) | TACR1 | |
| SCHEMBL2806816 | 0.69 | SERPINE1 (0.60) | TACR1 | |
| SCHEMBL6091766 | 0.64 | FOLH1 (0.47) | — | |
| SCHEMBL4096172 | 0.61 | FEN1 (0.35) | PTGESFEN1 | |
| SCHEMBL4638473 | 0.61 | ALDH1A1 (0.65) | — | |
| SCHEMBL5633633 | 0.61 | BRD4 (0.53) | TACR1 | |
| SCHEMBL4637805 | 0.61 | GAA (0.52) | TACR1 | |
| SCHEMBL7035090 | 0.59 | CCR2 (0.49) | — | |
| SCHEMBL1892197 | 0.59 | ERCC5 (0.46) | FEN1 | |
| SCHEMBL15093852 | 0.59 | CES2 (0.43) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | TACR1 1932/4885PTGES 3/4885FEN1 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.